In this article, we present five cases with this paradoxical side effect developing after anti-TNF treatment accompanied by the literature with the aim of aiding in finding an approach to these cases.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:The use of anti-tumor necrosis factor (anti-TNF) therapies for treatment of rheumatic diseases is increasing every day and the results are positive.
📊
Temel Bulgular & Veri:Case reports about skin reactions developing after use of these medications - newly developing psoriasis, increase/flare-up of existing psoriasis - are found in the literature at rates that cannot be ignored.
💡
Sonuç & Katkı:In this article, we present five cases with this paradoxical side effect developing after anti-TNF treatment accompanied by the literature with the aim of aiding in finding an approach to these cases.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Özet
The use of anti-tumor necrosis factor (anti-TNF) therapies for treatment of rheumatic diseases is increasing every day and the results are positive. Case reports about skin reactions developing after use of these medications - newly developing psoriasis, increase/flare-up of existing psoriasis - are found in the literature at rates that cannot be ignored. Psoriasis developing after the use of these agents for treatment is a paradoxical side effect, with no clear understanding of the cause though several hypotheses exist. In this article, we present five cases with this paradoxical side effect developing after anti-TNF treatment accompanied by the literature with the aim of aiding in finding an approach to these cases.
🔖
Bu Makaleye Atıf Yap
KUTLUK, Ö., ENGİNAR, A. Ü., BALCI, N., BÜTÜN, B., KAÇAR, C. (2019). Skin Reactions Developing After Anti-Tumor Necrosis Factor Treatment: A Paradoxical Side Effect. art, Cilt: 34 - Sayı: 1, 100–104. https://ajindex.com/articles/149680
López-Robles A, Queiro R, Alperi M, Alonso S, Riestra JL, Ballina J. Psoriasis and psoriasiform lesions induced by TNFa antagonists: the experience of a tertiary care hospital from northern Spain. Rheumatol Int 2012;32:3779-83
Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010;40:233-40
Gannes G, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31
Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 2005;102:3372-7
González-López MA, Martínez-Taboada VM, González-Vela MC, Fernández-Llaca H, Val-Bernal JF. New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br J Dermatol 2008;158:1146-8
Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007;56:2715-8
Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001
Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving antitumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009;68:209-15.